Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Still a Buy?

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up before the market opened on Thursday . The stock had previously closed at $18.02, but opened at $18.91. Daiichi Sankyo shares last traded at $18.2650, with a volume of 9,132 shares.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce”.

Daiichi Sankyo Price Performance

The stock has a market cap of $34.07 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.47 and a beta of -0.11. The company has a quick ratio of 1.64, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The company’s 50-day moving average is $17.18 and its 200-day moving average is $17.34.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.